This prospective, multicenter, randomized, controlled study aims to evaluate the efficacy and
safety of sorafenib combined with transarterial chemoembolization (TACE) in advanced
hepatocellular carcinoma (HCC) patients compared with sorafenib alone, and to determine the
prognostic factors that influence the survival.
Data on the efficacy and safety of sorafenib in combination with TACE in patients with
advanced HCC are lacking. Because in western countries, advanced HCC is considered as a
contraindication for TACE treatment. However, clinical practice patterns differ markedly
between Asia and western countries: in Asia TACE is performed in selected advanced HCC
patients. We consider sorafenib combined with TACE could achieve better survival benefit than
sorafenib alone in selected advanced HCC patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Air Force Military Medical University, China Fourth Military Medical University